SCHEMBL25019291

SCHEMBL25019291

CC1(C(=O)N[C@H]2CC[C@H](C)CC2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.50
HPGD P15428 2/20 0.41
RAB9A P51151 5/20 0.39
NPC1 O15118 4/20 0.39
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ADRA2A P08913 1/20 0.38
TAS1R3 Q7RTX0 2/20 0.38
TAS1R1 Q7RTX1 2/20 0.38
TAS1R2 Q8TE23 2/20 0.38
KDM4E B2RXH2 1/20 0.38
PRNP P04156 1/20 0.38
MMP2 P08253 1/20 0.38
MMP8 P22894 1/20 0.38
GAA P10253 2/20 0.37
MAPK1 P28482 1/20 0.37
GFER P55789 1/20 0.37
CCR2 P41597 1/20 0.36
USP2 O75604 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12020314 0.92 HPGD (0.46) EPHX1HPGDRAB9ANPC1SMN1; SMN2
SCHEMBL14161850 0.83 CCR2 (0.49) EPHX1HPGDRAB9ANPC1ALDH1A1
SCHEMBL28826594 0.82 CCR2 (0.51) EPHX1HPGDRAB9ANPC1ALDH1A1
SCHEMBL15906230 0.80 EPHX1 (0.50) EPHX1HPGDRAB9ANPC1ALDH1A1
SCHEMBL25018472 0.79 EPHX2 (0.42) EPHX1HPGDRAB9ANPC1ALDH1A1
SCHEMBL25018471 0.79 EPHX1 (0.54) EPHX1HPGDSMN1; SMN2GAACCR2
SCHEMBL20224881 0.78 EPHX1 (0.45) EPHX1HPGDKDM4ECCR2
SCHEMBL15906215 0.78 EPHX1 (0.48) EPHX1HPGDRAB9ANPC1ALDH1A1
SCHEMBL18377459 0.78 HPGD (0.40) EPHX1HPGDALDH1A1MMP2MMP8
SCHEMBL20194660 0.78 HPGD (0.55) EPHX1HPGDRAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183217-A1 INHIBITORS OF LRRK2 KINASE HALIA THERAPEUTICS INC (US) 2023-06-15 US disclosed
US-20230183217-A1 INHIBITORS OF LRRK2 KINASE HALIA THERAPEUTICS INC (US) 2023-06-15 US disclosed
US-11578061-B2 Inhibitors of LRRK2 kinase Halia Therapeutics, Inc. (US) 2023-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183217-A1 INHIBITORS OF LRRK2 KINASE LRRK2, SNCA, PRKAR2B EPHX1 3742/4885HPGD 3820/4885RAB9A 152/4885
US-11578061-B2 Inhibitors of LRRK2 kinase LRRK2, SNCA, PRKAR2B EPHX1 3742/4885HPGD 3820/4885RAB9A 152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.